Vivimed Labs
- Market cap
- ₹ 51 Cr.
- P/E
- 3x
- 52-week range
- 4.75 – 29.4
- ROCE
- −65%
- Dividend yield
- 0%
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Vivimed Labs Limited is an India-based company engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. The Company is primarily engaged in Pharma segment. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. Its manufacturing facilities are equipped to deliver a range of dosage delivery formats that include capsules, tablets, syrups & liquids, sprays & ointments.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Vivimed Labs against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)3 against a typical 34.6: cheaper than most peers (1st = cheapest).2nd of 220
- Sales growth−53.8% against a typical +15.6% from a year earlier.187th of 197
- Share price, 3 months+10.8% against a typical −0.5%.61st of 200
- Size₹ 50.7 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).164th of 199
Latest announcements
Exchange filings and their impact on the company.
- FY26 loss widened to Rs 176 cr and NCLT started insolvency on 15 Apr 2026, leaving equity deeply negative.
Vivimed Labs reported audited FY26 consolidated revenue of about Rs 70 cr with a net loss of about Rs 176 cr, including a Rs 23.3 cr inventory write-down. The auditor gave a qualified opinion for Rs 62.6 cr of unrecorded interest, flagged going-concern risk, and noted a CBI probe. After year-end, NCLT admitted insolvency (CIRP) on 15 April 2026 and appointed an IRP, leaving net worth deeply negative.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
No up-to-date rating
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE D; ISSUER NOT COOPERATING* | — | 16 Oct 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 16 Oct 2025 | Reaffirmed | CARE D | — | CARE | ₹ 376.43 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 17 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 30 May 2026 | Financial Results | VIVIMEDLAB : 30-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 28, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 30, 2026, To consider and approve the financial results for the period ended March 31, 2026 |
| 28 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 13 Mar 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 13 Feb 2026 | Board meeting Rescheduled | Vivimed Labs Limited has informed the Exchange that the meeting of the Board of Directors of the Company scheduled to be held on February 13, 2026 To consider and approve the financial results for the period ended December 31, 2025 has been postponed |
| 13 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 35 | 34 | 41 | 39 | 29 | 25 | 37 | 26 | 21 | 21 | 16 | 12 |
| Expenses | 36 | 40 | 40 | 67 | 40 | 25 | 35 | 28 | 22 | 22 | 27 | 152 |
| Operating Profit | 0 | −6 | 1 | −28 | −11 | −1 | 1 | −2 | 0 | −1 | −11 | −140 |
| OPM % | −0.9% | −18% | 3.1% | −74% | −37% | −2.6% | 2.9% | −10% | −1.3% | −4.6% | −68% | −1,169% |
| Other Income | 0 | 2 | 0 | 8 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 6 |
| Interest | 11 | 12 | 13 | −33 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 1 |
| Depreciation | 5 | 5 | 5 | 6 | 4 | 4 | 7 | 6 | 5 | 5 | 5 | 12 |
| Profit before tax | −16 | −20 | −17 | 7 | −15 | −5 | −6 | −5 | −5 | −7 | −17 | −147 |
| Tax % | 0% | 0% | −3% | 21% | 0% | 0% | 0% | 2% | 0% | 0% | 0% | 0% |
| Net Profit | −16 | −20 | −16 | 5 | −15 | −5 | −6 | −6 | −5 | −7 | −17 | −147 |
| EPS in Rs | −1.88 | −2.45 | −1.94 | 0.63 | −1.84 | −0.62 | −0.72 | −0.68 | −0.66 | −0.88 | −2 | −17.74 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −26%
- 5 Years
- −39%
- 3 Years
- −28%
- TTM
- −40%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 14%
- TTM
- −452%
- 10 Years
- −26%
- 5 Years
- −23%
- 3 Years
- 4%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
Peers
Listed companies in the same business.
| Vivimed Labs | ₹ 6.21 | ₹ 51 Cr. | 3x | — | — | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.9x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 74x | 11.6x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 76.4x | 20.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28x | 3.4x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.3x | 4.3x | 19.7% | 18.5% |
Management
- V. Manohar Rao
- Executive Non-Independent Chairman of the Board
- Santosh Varalwar
- Managing Director, Executive Non-Independent Director
- Sandeep Varalwar
- Whole Time Non-Independent Director
- K. Yugandhar
- Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.